Nancy A. Dreyer,
MPH, PhD
Global Chief, Sci Affairs; Sr VP, Head, Center for Advanced Evidence Generation
IQVIA
Dr. Nancy Dreyer is the chief scientific officer and global chief of scientific affairs for IQVIA Real-World & Analytic Solutions. She leads the Center for Advanced Evidence Generation, focusing on the use of real-world evidence for regulators, payers, clinicians, and patients using minimally interventional and non-interventional study design that rely on primary and/or secondary data collection. She has worked with the FDA, most recently helping to plan a medical device evaluation network, and also has worked with the European Medicines Agency testing new methods for pharmacovigilance. Dr. Dreyer also leads programs on sports injury surveillance and analytics for the National Football League and for the National Basketball Association.
Well-known internationally, Dr. Dreyer is a senior editor of the “Registries for Evaluating Patient Outcomes: A User’s Guide,” published by the US Agency for Research on Healthcare and Quality, now in its third edition with translations in Chinese and Korean. She also led the GRACE Initiative for Good Research Practices for Observational Studies of Comparative Effectiveness.
Dr. Dreyer is a Fellow of both the International Society for Pharmacoepidemiology Research and DIA. She earned a doctorate in epidemiology and master’s degree in public health from the University of North Carolina at Chapel Hill.
Fellows of DIA
-
PhD •Chair, Fellows of DIA
President, Japan Self-Medication Industry -
-
JD • President, B-Henry & Associates -
MD, PhD • Pharmacovigilance Expert -
MD • Professor of Clinical Pharmacology, St. Vincent's Hospital -
MBA • President, International Regulatory Affairs Group LLC -
MPH, PhD • Global Chief, Sci Affairs; Sr VP, Head, Center for Advanced Evidence Generation
IQVIA -
PhD • Senior Advisor, Strategic Programs,Center for Drug Evaluation and Research, US Food and Drug Administration -
MD • Senior VP, Chief Medical Officer, Director, Corporate Medical Affairs HQ, Eisai Co., Ltd. -
MBA • Chairman, CISCRP; Director of Sponsored Research, Tufts Center For the Study of Drug Development -
PhD • Corporate Vice President
PAREXEL International -
MD • Senior Vice-President, Industrie Sante -
MD • Deputy Director, FDA Liaison to the EMA, Office of International Programs, OC -
MD • Deputy Director, Integrated Delivery, and Lead for Global Regulatory Systems Initiatives
Bill and Melinda Gates Foundation -
MD, JD • Senior Vice President, Head of Global Regulatory Affairs and Clinical Safety, Merck & Co., Inc. -
MS • Representative, NM Consulting -
PhD • Advisor, Digital Channels and eCapabilities, Eli Lilly and Company -
MD • Chief Medical Officer & EVP, Horizon Pharma, Inc. -
DVM, MBA • Director Biopeople, University of Copenhagen -
PhD • Professor and Director, Institute of Drug Regulatory Science, Shenyang Pharmaceutical University, Venture Partner, Lilly Asia Ventures